GLP-1 (Glucagon-Like Peptide-1) medications, such as Semaglutide or Tirzepatide, are a revolutionary class of drugs used in weight management
Here, we examined the effects of ARTHS mutations on histone acetylation in human cells and the effects of heterozygous loss of Kat6a in mice ( Kat6a +/ ) on learning, memory, activity, and sociability
10.3390/ijms25158013 74 ShoskesA.ZhouL.YingH.GardenerH.AlkhachroumA.YinR.et al (2025)
It's not well absorbed

For patients interested in participating in research , the following resources may be helpful: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) search for Parkinson's and GLP-1 trials Parkinson's UK (www.parkinsons.org.uk) information on current research and trial opportunities When to contact your GP or specialist : If you have Parkinson's disease and diabetes, and wish to discuss whether a GLP-1 receptor agonist is appropriate for your diabetes management If you experience new or worsening symptoms whilst taking any medication If you are interested in clinical trial participationyour neurologist can advise on suitable studies Seek urgent medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Persistent vomiting or inability to keep fluids down (risk of dehydration) Signs of dehydration (extreme thirst, dark urine, dizziness) Allergic reaction (rash, swelling, difficulty breathing) Patients should never start, stop, or modify medications without medical supervision
